Le Lézard
Classified in: Health
Subject: FDA

Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease

SAN DIEGO, April 24, 2019 /PRNewswire/ -- Belite Bio, a drug development company targeting currently untreatable conditions in ophthalmology and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration.  LBS-008 will be one of the first drugs to graduate from the US National Institute of Health's (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which has funded LBS-008's discovery and development, and will continue to provide support and funding until the completion of its Phase 1 single ascending dose (SAD) clinical trial.

"Initiation of the Phase 1 trial is an important milestone for LBS-008, which was funded by the NIH Blueprint Program starting from lead optimization to a preclinical proof of concept," said Dr. Konstantin Petrukhin, Associate Professor of Ophthalmic Science at Columbia University Medical Center, and inventor of the technology. "LBS-008 is expected to bring hope to millions of patients suffering from untreatable forms of macular degeneration."

"We are excited to announce the start of this Phase 1 trial in the US together with the NIH," said Dr. Tom Lin, Chairman of Belite Bio. "We're encouraged by the ongoing favorable regulatory view of our technology, including a systematic review published by the UK National Institute for Health Research identifying reduction of RBP4 as the most promising treatments for dry AMD and Stargardt disease. We plan to continue to work closely with our collaborators to the next clinical and regulatory milestone."

About LBS-008
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins (A2E) in the eye that cause Stargardt disease and contribute to atrophic Age-related Macular Degeneration (dry AMD).

Belite Bio holds the worldwide exclusive rights for LBS-008. LBS-008 received US and EU orphan drug designation (ODD) in 2017 and 2018, and rare pediatric disease designation (RPD) from the FDA in 2018 for the treatment of Stargardt disease.

About Belite Bio
Belite Bio, a subsidiary of Lin BioScience, is a San Diego based clinical stage biopharmaceutical company targeting untreatable diseases, including age-related macular degeneration, Stargardt disease, and liver diseases. For more information, please visit www.belitebio.com.


SOURCE Belite Bio, Inc

These press releases may also interest you

3 avr 2020
One-day mobile collections for COVID-19 testing specimens are continuing this weekend and into early next week, with the University of Mississippi Medical Center, Mississippi State Department of Health, Mississippi Emergency Management Agency and...

3 avr 2020
Cheeriodicals today announced the delivery of more than 200 personalized cheer-up gifts to pediatric patients at Cottage Children's Medical Center and to Veteran patients at Santa Barbara Veterans Affairs Clinic.  Cheeriodicals' gifts are made up of...

3 avr 2020
Kaiser Permanente has announced that it will waive all member out-of-pocket costs for inpatient and outpatient services related to the treatment of COVID-19, as of April 1, 2020. This is intended to alleviate the cost burden and stress on impacted...

3 avr 2020
The management of Olymel deplores the untruthful and irresponsible information that an anonymous person circulated on social networks on Friday April 3 to the effect that products from his pork processing facility in Yamachiche could transmit the...

3 avr 2020
As more states are ordering businesses to temporarily close and millions of residents to stay at home because of the coronavirus, Rx relief, a division of PrideStaff, is proud to partner with essential businesses and healthcare organizations, helping...

3 avr 2020
United Security Health and Casualty Insurance Company (United Security) recently received authorization to offer its Short Term Major Medical (STMM) plan in the state of Oklahoma. Lisa Cordero, COO, United Security began, "A Short Term Major Medical...

News published on 24 april 2019 at 10:15 and distributed by: